A multicenter, blinded, placebo-controlled study to investigate the effects of everolimus and/or BEZ235 on the immune response to vaccination in the elderly.
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2016
Price : $35 *
At a glance
- Drugs Dactolisib (Primary) ; Everolimus; Influenza virus vaccine (Afluria); Influenza virus vaccine (Afluria)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Novartis Institutes for BioMedical Research
- 08 Jun 2016 Status changed from active, no longer recruiting to completed.
- 21 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by Australian New Zealand Clinical Trials Registry.
- 05 Feb 2014 New trial record